clinical trials

News

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

News

Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward.

News

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

News

Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.

News

Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.

News

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.